ZAP Surgical Systems, Inc. articles

ZAP Surgical Systems, Inc. today announced it has received CE mark clearance to the new EU MDR for its ZAP-X® Gyroscopic Radiosurgery® platform. The CE mark makes it possible for healthcare providers to begin treating patients with the ZAP-X system in the European Union.

For select indications including many primary and metastatic brain tumors, stereotactic radiosurgery (SRS) is proven to be an effective alternative to invasive surgeries. As a non-invasive outpatient procedure

ZAP Surgical Systems, Inc. today announced it has received Shonin approval from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for its ZAP-X® Gyroscopic Radiosurgery® platform. As part of the approval, ZAP-X is now cleared for clinical use in Japan.

To facilitate a robust market introduction effort, ZAP also announced a partnership with MC Medical Inc. to lead Japanese sales and marketing initiatives. Joining the effort, a partnership with Chiyoda Technol Corpo

Neurosurgery, Cyberknife Center, Centro Diagnostico Italiano, Milano, ITA 2. Department ofRadiation Oncology – Radiation Physics, Stanford University School of Medicine, Palo Alto, USA 3.Department of Neurosurgery, Stanford University School of Medicine, Palo Alto, USA 4. Engineering, ZapSurgical Systems, San Carlos, USA 5.